The News

NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board

07/06/2007

Berlin, Germany June 8, 2007 -- NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the appointment of Dr. Walter Wenninger as the Company’s new Chairman of the Supervisory Board. The appointment follows NOXXON’s successful closing of a 37 million Euro (50 million US $) series C round of financing in early May. Dr. Wenninger succeeds Dr. Axel Polack, General Partner of TVM Capital, who had served as interim Chairman and who will remain a member of the Board.

“Dr. Wenninger brings over 30 years of experience in R & D, financial, business and operating management," said Dr. Sven Klussmann, NOXXON’s CEO and CSO. “We are honored to have him chair our Board of Directors, and we look forward to benefiting from his experience and insight as we continue to advance our products.
“We are pleased to be able to attract someone with Dr. Wenninger's extensive background" said Dr. Axel Polack. "His broad experience in all the different aspects of drug development and marketing will be extremely valuable to NOXXON."

Dr. Wenninger commented on his appointment: “As Chairman of NOXXON, I look forward to leverage my experience to support the transition of the company from a drug discovery to a drug development organization in the field of oligonucleotide therapeutics. I am honored by the appointment and look forward to this exciting task.” In his long and distinguished career Dr. Wenninger held numerous executive positions in the life science business of Bayer AG, including 6 years as member of the Management Board. Following his retirement at Bayer, Dr. Wenninger has been involved in the strategic positioning and development of several companies and organisations. He currently serves on the boards of various European pharmaceutical companies. In addition he is a member of the Executive Committee of the German Cardiac Research Foundation, the Executive Committee of the Robert-Koch- Foundation, and until recently a long time member of the Board of Trustees of the German Cancer Research Center.

About NOXXON Pharma AG:
Based on one of the biggest and best protected patent portfolios in the industry, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word “Spiegel” means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics. Website info: http://www.noxxon.net/ General contact: Emmanuelle Camerer NOXXON Pharma AG

Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49 30 72 62 47 0
FAX: + 49 30 72 62 47 225
Email: ecamerer@noxxon.net